[Ranitidine, a newly developed histamine H2-receptor antagonist. First experimental and clinical results].
D000818:Animals; D001682:Biological Availability; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000188:drug therapy; D005663:Furans / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use; D006635:Histamine H2 Antagonists / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007700:Kinetics; D011899:Ranitidine; D012008:Recurrence; D013997:Time Factors; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy
D005663:Furans; D006635:Histamine H2 Antagonists; D011899:Ranitidine
Ranitidin, ein neu entwickelter Histamin-H2-Rezeptor-Antagonist. Erste experimentelle und klinische Daten.